These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15886799)

  • 1. Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
    Koenen RR; Christella M; Thomassen LG; Tans G; Rosing J; Hackeng TM
    Thromb Haemost; 2005 May; 93(5):853-9. PubMed ID: 15886799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
    Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J
    Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
    Tans G; van Hylckama Vlieg A; Thomassen MC; Curvers J; Bertina RM; Rosing J; Rosendaal FR
    Br J Haematol; 2003 Aug; 122(3):465-70. PubMed ID: 12877675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired APC resistance and oral contraceptives: differences between two functional tests.
    Curvers J; Thomassen MC; Nicolaes GA; Van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Br J Haematol; 1999 Apr; 105(1):88-94. PubMed ID: 10233368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
    Tchaikovski SN; Thomassen MC; Costa SD; Bremme K; Rosing J
    Thromb Res; 2014 Nov; 134(5):1032-7. PubMed ID: 25260941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation.
    Koenen RR; Tans G; van Oerle R; Hamulyák K; Rosing J; Hackeng TM
    Blood; 2003 Sep; 102(5):1686-92. PubMed ID: 12730108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between extrinsic activated protein C resistance and venous thromboembolism in women.
    Heinemann LA; Kluft C; Spannagl M; de Maat MP
    Contraception; 2002 Nov; 66(5):297-304. PubMed ID: 12443958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the APTT- and ETP-based APC sensitivity tests.
    de Visser MC; van Hylckama Vlieg A; Tans G; Rosing J; Dahm AE; Sandset PM; Rosendaal FR; Bertina RM
    J Thromb Haemost; 2005 Jul; 3(7):1488-94. PubMed ID: 15978106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
    Brugge JM; Tans G; Rosing J; Castoldi E
    Thromb Haemost; 2006 Feb; 95(2):236-42. PubMed ID: 16493484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
    Rosing J; Hemker HC; Tans G
    Semin Thromb Hemost; 1998; 24(4):329-35. PubMed ID: 9763350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide.
    Deguchi H; Bouma BN; Middeldorp S; Lee YM; Griffin JH
    J Thromb Haemost; 2005 May; 3(5):935-8. PubMed ID: 15869587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
    Curvers J; Christella M; Thomassen LG; de Ronde H; Bertina RM; Rosendaal FR; Tans G; Rosing J
    Thromb Haemost; 2002 Mar; 87(3):483-92. PubMed ID: 11924538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
    Rühl H; Schröder L; Müller J; Sukhitashvili S; Welz J; Kuhn WC; Oldenburg J; Rudlowski C; Pötzsch B
    PLoS One; 2014; 9(8):e105007. PubMed ID: 25121606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
    Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J
    Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.